To be realistic and to taper my expectations, I would be expecting an announcement that would headline only its good safety profile that would consist of no significant safety issues and no severe grade adverse events on the low dose cohort.
Since it is a low dose cohort, it is unlikely to generate significant efficacy data, but its safety would be favoured. If this is the case, then the market would probably not move significantly, as it doesn't fully de-risk the product for new and big investors to jump in.
However, if they do show efficacy data at such a low dose either by showing the tumour response rate, overall survival, or even its pharmacodynamic activities, then I think the market would be bullish and expect a significant increase in share price.
If there are safety issues at the lowest cohort dose, well then prepare for a significant drop in share price. I think this is highly unlikely because if there are significant issues in the lowest dose cohort then the trial would be halted or cancelled by the FDA and/or ethics committees.
So your worst case scenario is the price stays the same with just a good safety data and the best case is hopefully breaking that ATH with good safety and some efficacy data.
CHM Price at posting:
31.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)